Case Based Roundtable Series - Targeted Oncology
6 days ago · Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.
Dostarlimab Delivers Impressive Results in Rectal Cancer, But More ...
Jun 24, 2024 · Dostarlimab-gxly (Jemperli), a PD-1 inhibitor and immunotherapy drug, has shown remarkable potential in the treatment of patients with colorectal cancer, specifically in those with locally advanced mismatch repair-deficient (dMMR) rectal cancer.
Advancements in Follicular Lymphoma Treatment With Targeted …
Nov 14, 2024 · The treatment options for follicular lymphoma (FL) are rapidly advancing, driven by the development of new, promising therapies. At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory FL.
Maintenance Therapies in Metastatic Colorectal Cancer - Targeted …
Oct 4, 2021 · Kanwal Raghav, MBBS, MD: Maintenance therapy is a fairly common method that we apply in colorectal cancer, partly because the response from chemotherapy is pretty good in first-line treatment. Most patients will benefit from chemotherapy initially, but at some point, toxicities become limiting. This becomes more of an issue with oxaliplatin-based treatments than with irinotecan-based treatments.
Case Presentation: A 57-Year-Old Woman With Ovarian Cancer
Sep 23, 2021 · Lyndsay Willmott, MD: We’d like to discuss a patient who’s presenting with classic symptoms of ovarian cancer. This is a 57-year-old woman who presented with progressive abdominal discomfort and bloating, as well as early satiety, new onset constipation, and unintentional weight loss.
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.
Progression After R-CHOP: What Next? - Targeted Oncology
May 3, 2019 · Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.
Abemaciclib With ET Outperforms Chemotherapy in Advanced …
Sep 16, 2024 · Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard chemotherapy in patients with advanced breast cancer.
Trastuzumab Deruxtecan Shows Activity in Real-World mBC With …
Dec 7, 2023 · A study investigating real-world patients who received trastuzumab deruxtecan (T-DXd; Enhertu) for advanced breast cancer (aBC) revealed valuable data on its efficacy in patients whose HER2 expression status switched during treatment. 1 In 191 real-world patients with HER2-positive (HER2+), HER2-low, and HER2-0 status, the median time to next treatment (TTNT) after T-DXd was 10.4 months, 7.6 ...